News | January 29, 2015

University of Oklahoma Proton Therapy System Enters Clinical Commissioning

Mevion S250 delivers treatment advantages, capabilities of larger proton therapy system in smaller footprint

Mevion, S250, proton therapy, radiation, University of Oklahoma, commissioning

January 29, 2015 — Mevion Medical Systems is announcing that the Mevion S250 proton therapy system at the Stephenson Cancer Center at the University of Oklahoma has completed its rigorous acceptance testing and is now entering the clinical commissioning phase. Clinical commissioning is the final step before physicians begin treating patients with the system.

“Providing an advanced proton therapy system for our patients will allow the Stephenson Cancer Center to remain in the forefront of cancer treatment,” said Ozer Algan, M.D., director of proton therapy at the Stephenson Cancer Center. 

During four weeks of acceptance testing, the Mevion S250 was put through a series of demanding tests to validate that it meets precise technical and clinical performance requirements. The system was shown to meet or exceed all specifications, and its operational control has been officially transitioned to the physics and radiation oncology proton teams at the Stephenson Cancer Center. 

“We look forward to treating our first patient with this innovative technology,” said Mike Samis, chairman of the University Hospitals Authority and Trust. “We are committed to clinical innovation and medical excellence, and this first-of-its-kind proton therapy system is a welcome addition to the comprehensive list of cancer services we offer our patients.”

Proton therapy targets cancer cells more precisely than traditional photon radiation treatment and results in less damage to surrounding healthy tissue and organs. Because of this, it is ideal for treating pediatric patients and adult patients with cancers in sensitive locations, such as near the brain, spine, heart and lungs.  

The Mevion S250 delivers the same treatment advantages and capabilities of significantly larger and more expensive proton therapy systems but with a much smaller footprint, improved reliability, more efficient patient access, and dramatically lower capital and operational costs.  

For more information: www.mevion.com

Related Content

Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.